高级检索
当前位置: 首页 > 详情页

Synthesis and Biological Evaluation of Heterocyclic Substituted Bis(indolyl)methanes

文献详情

资源类型:
Pubmed体系:
机构: [1]College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, China. [2]Central Laboratory, The NO.1 Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650021, China. [3]Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, China.
出处:
ISSN:

摘要:
Bis(indolyl)methane derivatives are widely found in nature with a broad range of biological and pharmacological activities. The development of techniques for the synthesis and functionalization of bis(indolyl)methanes have attracted more and more attention in recent years.To study the synthesis and biological activity of heterocyclic substituted bis(indolyl)methanes.A series of heterocyclic substituted bis(indolyl)methanes (3a-3p) have been prepared by condensation reaction of indole and heterocyclic aldehydes catalyzed by boron trifluoride etherate with high yields. Preliminary in vitro anti-inflammatory in lipopolysaccharide (LPS)-stimulated RAW-264.7 macrophages and cytotoxic activity against human tumor cell lines (A549, Hela and SGC7901) by MTT assay were tested.The result indicated that heterocyclic substituted bis(indolyl)methanes showed good antiinflammatory and selective cytotoxic activity. Especially, compounds 3o, 3p and 3q displayed similar inhibitory effect on the generation of NO to positive control dexamethasone, and compound 3q displayed similar selective cytotoxic activity to 5-FU.Heterocyclic substituted bis(indolyl)methanes may be used as potential anti-inflammatory and anticancer leads.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 化学
小类 | 4 区 有机化学
最新[2023]版:
大类 | 4 区 化学
小类 | 4 区 有机化学
第一作者:
第一作者机构: [1]College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, China.
共同第一作者:
通讯作者:
通讯机构: [1]College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, China. [2]Central Laboratory, The NO.1 Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650021, China. [*1]Central Laboratory, The No.1 Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650021, P.R. China [*2]College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82605 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号